JP6857644B2 - 直腸の炎症性変化の治療用医薬製剤 - Google Patents
直腸の炎症性変化の治療用医薬製剤 Download PDFInfo
- Publication number
- JP6857644B2 JP6857644B2 JP2018500330A JP2018500330A JP6857644B2 JP 6857644 B2 JP6857644 B2 JP 6857644B2 JP 2018500330 A JP2018500330 A JP 2018500330A JP 2018500330 A JP2018500330 A JP 2018500330A JP 6857644 B2 JP6857644 B2 JP 6857644B2
- Authority
- JP
- Japan
- Prior art keywords
- budesonide
- suppository
- solid fat
- pharmaceutical
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000664 rectum Anatomy 0.000 title claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- 230000002757 inflammatory effect Effects 0.000 title description 2
- 239000000829 suppository Substances 0.000 claims description 154
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 131
- 229960004436 budesonide Drugs 0.000 claims description 131
- 239000003925 fat Substances 0.000 claims description 58
- 239000007787 solid Substances 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 32
- 238000003860 storage Methods 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 239000003963 antioxidant agent Substances 0.000 claims description 21
- 235000006708 antioxidants Nutrition 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 20
- 230000003078 antioxidant effect Effects 0.000 claims description 19
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 18
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims description 18
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 18
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 16
- 229960004963 mesalazine Drugs 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 235000002316 solid fats Nutrition 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 206010036774 Proctitis Diseases 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 6
- 206010036783 Proctitis ulcerative Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 description 54
- 239000004480 active ingredient Substances 0.000 description 47
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000006641 stabilisation Effects 0.000 description 8
- 238000011105 stabilization Methods 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 241000792859 Enema Species 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000007920 enema Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229920001684 low density polyethylene Polymers 0.000 description 5
- 239000004702 low-density polyethylene Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- 229920000915 polyvinyl chloride Polymers 0.000 description 5
- 239000004800 polyvinyl chloride Substances 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 4
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 239000005033 polyvinylidene chloride Substances 0.000 description 4
- 150000004671 saturated fatty acids Chemical class 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002511 suppository base Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940095399 enema Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000011417 postcuring Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000005001 laminate film Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010137 moulding (plastic) Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(a)医薬有効成分としての、適切な粒径分布におけるブデソニドの使用、
(b)適切な固形脂肪品質の選択、
(c)前記固形脂肪基剤への、酸化防止剤としてのアスコルビン酸パルミテートの最適化された濃度での添加、
(d)前記固形脂肪基剤中に溶解しているブデソニドと懸濁しているブデソニドとの最適比率の調整、
(e)記載の投与に適した坐剤形態および坐剤サイズそれぞれの使用、ならびに
(f)包装体としての低酸素透過性キャストフィルムの使用。
この評価基準および関連するパラメータの定義は、該文献の表1に開示されている。
溶融状態にある40℃のウィテップゾールH15に対するブデソニドの溶解度を求めた。ここでは、ブデソニドの量を増しながら、固形脂肪基剤中に懸濁させた。未溶解のブデソニドを分離し、坐剤を固化させた後、HPLC/UVを用いて、溶解した割合および溶解しなかった割合をそれぞれ求めた。結果を以下に示す。
適切な酸化防止剤を選択するために、従来技術に記載のある、種類の異なる酸化防止剤について試験した。ここでは、質量1.8gのブデソニド2mg坐剤を使用したが、該坐剤中の有効成分は、固形脂肪基剤中に完全に溶解した状態で含まれていた。酸化防止剤は濃度が100ppmとなるように、製剤に添加された。対照バッチは、酸化防止剤を含まないものとした。成形型として、低密度ポリエチレン(LDPE)でコーティングされたポリ塩化ビニルフィルム(PVC)から成るラミネートフィルムを使用した。このフィルムは、ポリ塩化ビニリデン(PVdC)でできたさらなるバリア層は含まないものであった。各坐剤は、30℃/相対湿度65%で30日間貯蔵した。調製および貯蔵の後、ブデソニド坐剤の不純物プロファイルをHPLC/UVを用いて測定した。以下2つの表は、試験した製剤および試験結果をまとめたものである。
ブデソニドを安定化するための酸化防止剤としてのアスコルビン酸パルミテートの効果を、以下の処方のブデソニド2mg坐剤を用いて試験した。
好ましい実施形態において、100ppmのアスコルビン酸パルミテートを用いてブデソニド2mg坐剤および4mg坐剤を調製し、有効期間試験のために25℃/相対湿度60%で貯蔵した。製造直後、および貯蔵中に一定の間隔を置いて、坐剤中の含量および純度をHPLC/UVで測定した。以下2つの表は、ブデソニド2mg坐剤およびブデソニド4mg坐剤の結果をまとめたものである。
本発明によって組成され調製されたブデソニド坐剤は、2時間にわたって有効成分を放出する。この間に、微粉化状態で懸濁されている有効成分および固形脂肪基剤に溶解して分子が分散している有効成分のいずれもが放出される。これによって、十分に長い時間にわたって有効成分を直腸粘膜上で利用できることになり、治療効果を確実に発揮させることができる。図1に、ブデソニド2mg坐剤バッチV2042の、製造直後(T0)および25℃/相対湿度60%において24ヶ月間貯蔵した後(T24)の放出プロファイルを示す。測定は37℃で実施し、好ましくはヨーロッパ薬局方に記載のフローセル(装置4)を使用し、流速16ml/分の閉鎖系とする。媒体として、0.5%のドデシル硫酸ナトリウムを添加したpH6.8のクエン酸リン酸緩衝液を使用する。放出動態を明らかにするために、15分後、30分後、45分後、60分後、90分後、および120分後にサンプリングを行う。放出媒体に溶解しているブデソニドは、HPLC/UVで測定する。
二重盲検試験として、直腸炎の患者に対するブデソニド坐剤の試験を行った。合計79名の患者に対する治療により、異なる有効成分を含む様々な坐剤についての試験を行ったが、どの坐剤が投与されているのか、患者には知らされなかった。
Claims (11)
- 直腸内に投与するための医薬製剤であって、ブデソニドまたはその薬学的に適合する塩、および1種類の固形脂肪または複数種の固形脂肪の混合物を製剤の総重量に対して少なくとも80重量%含み、さらにこれらの成分と適合する酸化防止剤を少なくとも1種含み、該酸化防止剤がアスコルビン酸パルミテートであり、固形脂肪のトリグリセリド含有率が80重量%以上であり、固形脂肪のヒドロキシル価が1〜15であり、固形脂肪の不飽和脂肪酸含有率が1重量%未満であり、経肛門投与用の坐剤であり、坐剤1個当たり1.8〜4.2mgのブデソニドを含み、坐剤1個当たりの重量が0.8〜1.2gであることを特徴とする、医薬製剤。
- 融点と凝固点との差が小さく、融点が33.5〜35.5℃、凝固点が32.5〜34.5℃であることを特徴とする、請求項1に記載の製剤。
- 坐剤1個当たり1.8〜2.2mgのブデソニドを含むことを特徴とする、請求項1または2に記載の製剤。
- 坐剤1個当たりのブデソニドの重量が3.8〜4.2mgであることを特徴とする、請求項1または2に記載の製剤。
- アスコルビン酸パルミテートの濃度が50〜200ppmであることを特徴とする、請求項1に記載の製剤。
- ブデソニドが微粉化された形態にあり、ブデソニド粒子の100%が10μmよりも小さいことを特徴とする、請求項1〜5のいずれかに記載の製剤。
- 請求項1〜6のいずれかに記載の製剤であって、該医薬製剤が坐剤の形態で気密キャストフィルム内に包装されていることを特徴とする製剤。
- 直腸の炎症性疾患の治療に使用するためのものである、請求項1〜7のいずれかに記載の医薬製剤。
- 急性潰瘍性直腸炎の治療に使用するためのものである、請求項1〜7のいずれかに記載の医薬製剤。
- メサラジン坐剤と併用されることを特徴とする、請求項8または9に記載の医薬製剤。
- 請求項1〜6のいずれかに記載の製剤の製造方法であって、医薬製剤の調製が酸素排除下で行われる工程を含み、該医薬製剤は貯蔵安定性を有することを特徴とする製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15175806.7A EP3115037B1 (de) | 2015-07-08 | 2015-07-08 | Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms |
EP15175806.7 | 2015-07-08 | ||
PCT/EP2016/064907 WO2017005524A1 (de) | 2015-07-08 | 2016-06-28 | Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018519345A JP2018519345A (ja) | 2018-07-19 |
JP6857644B2 true JP6857644B2 (ja) | 2021-04-14 |
Family
ID=53540667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018500330A Active JP6857644B2 (ja) | 2015-07-08 | 2016-06-28 | 直腸の炎症性変化の治療用医薬製剤 |
Country Status (23)
Country | Link |
---|---|
US (3) | US10905699B2 (ja) |
EP (2) | EP3115037B1 (ja) |
JP (1) | JP6857644B2 (ja) |
CN (1) | CN107847435B (ja) |
AU (1) | AU2016290343B2 (ja) |
CA (1) | CA2986081C (ja) |
DK (1) | DK3319586T3 (ja) |
EA (1) | EA033153B1 (ja) |
ES (2) | ES2688119T3 (ja) |
FI (1) | FI3319586T3 (ja) |
HR (1) | HRP20230174T1 (ja) |
HU (1) | HUE061585T2 (ja) |
IL (1) | IL255247B (ja) |
LT (1) | LT3319586T (ja) |
MA (1) | MA42367B1 (ja) |
MD (1) | MD3319586T2 (ja) |
PL (1) | PL3319586T3 (ja) |
PT (2) | PT3115037T (ja) |
RS (1) | RS64020B1 (ja) |
SI (1) | SI3319586T1 (ja) |
UA (1) | UA120075C2 (ja) |
WO (1) | WO2017005524A1 (ja) |
ZA (1) | ZA201707777B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115529815B (zh) * | 2021-04-27 | 2024-04-30 | 广州共禾医药科技有限公司 | 经直肠施用的奥司他韦或其药学上可接受的盐的药物组合物、及其制备方法和用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB701831A (en) * | 1950-10-19 | 1954-01-06 | Rudolf Von Wuelfing | Process for the production of suppositories containing medicaments |
US3208907A (en) * | 1961-11-13 | 1965-09-28 | Lab Toraude | Stabilized salicylate compositions |
DE3709861A1 (de) * | 1987-03-25 | 1988-10-06 | Henkel Kgaa | Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen |
JP2927830B2 (ja) * | 1989-09-01 | 1999-07-28 | 東京田辺製薬株式会社 | ダナゾール坐剤 |
IT1243379B (it) | 1990-07-27 | 1994-06-10 | Giuliani Spa | Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico |
DE29717252U1 (de) * | 1997-09-26 | 1998-02-19 | Falk Pharma Gmbh | Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen |
DE19849737A1 (de) * | 1998-10-28 | 2000-05-04 | Falk Pharma Gmbh | Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen |
US20020085978A1 (en) * | 2000-11-10 | 2002-07-04 | Mina Buenafe | Degradation-resistant glucocorticosteroid formulations |
CU23203A1 (es) * | 2002-12-27 | 2007-05-18 | Ct Ingenieria Genetica Biotech | Formulaciones que contienen agentes de accion trombolitica para su administracion por via rectal |
JP5223307B2 (ja) * | 2006-11-17 | 2013-06-26 | 大正製薬株式会社 | 坐剤 |
NZ581710A (en) * | 2007-06-13 | 2012-02-24 | Jay Pravda | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
CN102316889B (zh) * | 2008-11-26 | 2014-11-26 | 萨蒂奥根制药公司 | 组合物及使用方法 |
WO2012022796A2 (de) * | 2010-08-20 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Neue kombinationen |
CN102525883B (zh) * | 2010-12-09 | 2013-05-08 | 丽珠集团丽珠制药厂 | 一种伏立康唑栓剂及其制备方法和用途 |
WO2015073846A1 (en) | 2013-11-15 | 2015-05-21 | Salix Pharmaceuticals, Inc. | Method of treating ulcerative colitis |
-
2015
- 2015-07-08 EP EP15175806.7A patent/EP3115037B1/de active Active
- 2015-07-08 PT PT15175806T patent/PT3115037T/pt unknown
- 2015-07-08 ES ES15175806.7T patent/ES2688119T3/es active Active
-
2016
- 2016-06-28 MD MDE20180489T patent/MD3319586T2/ro unknown
- 2016-06-28 HR HRP20230174TT patent/HRP20230174T1/hr unknown
- 2016-06-28 EP EP16732617.2A patent/EP3319586B1/de active Active
- 2016-06-28 CA CA2986081A patent/CA2986081C/en active Active
- 2016-06-28 LT LTEPPCT/EP2016/064907T patent/LT3319586T/lt unknown
- 2016-06-28 EA EA201792685A patent/EA033153B1/ru unknown
- 2016-06-28 ES ES16732617T patent/ES2938358T3/es active Active
- 2016-06-28 AU AU2016290343A patent/AU2016290343B2/en active Active
- 2016-06-28 PL PL16732617.2T patent/PL3319586T3/pl unknown
- 2016-06-28 FI FIEP16732617.2T patent/FI3319586T3/fi active
- 2016-06-28 DK DK16732617.2T patent/DK3319586T3/da active
- 2016-06-28 PT PT167326172T patent/PT3319586T/pt unknown
- 2016-06-28 RS RS20230170A patent/RS64020B1/sr unknown
- 2016-06-28 HU HUE16732617A patent/HUE061585T2/hu unknown
- 2016-06-28 CN CN201680039904.2A patent/CN107847435B/zh active Active
- 2016-06-28 SI SI201631664T patent/SI3319586T1/sl unknown
- 2016-06-28 US US15/742,710 patent/US10905699B2/en active Active
- 2016-06-28 MA MA42367A patent/MA42367B1/fr unknown
- 2016-06-28 JP JP2018500330A patent/JP6857644B2/ja active Active
- 2016-06-28 WO PCT/EP2016/064907 patent/WO2017005524A1/de active Application Filing
- 2016-06-28 UA UAA201800685A patent/UA120075C2/uk unknown
-
2017
- 2017-10-24 IL IL255247A patent/IL255247B/en active IP Right Grant
- 2017-11-16 ZA ZA2017/07777A patent/ZA201707777B/en unknown
-
2020
- 2020-11-10 US US17/094,233 patent/US11738032B2/en active Active
-
2023
- 2023-07-12 US US18/221,164 patent/US20230364113A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3154529B1 (en) | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use | |
AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
CA2231342C (fr) | Composition pharmaceutique pour administration par voie orale | |
JP2002530335A (ja) | 急速経粘膜吸収を与えるニコチン含有医薬組成物 | |
KR101994129B1 (ko) | 통증 치료를 위한 셀레콕시브 경구용 조성물 | |
US20230364113A1 (en) | Pharmaceutical formulation for the treatment of inflammatory changes to the rectum | |
ES2833294T3 (es) | Composiciones sólidas de triglicéridos y usos de las mismas | |
US20200352853A1 (en) | Oral composition of celecoxib for treatment of pain | |
CN107979999B (zh) | 高浓度制剂 | |
WO2017190714A1 (es) | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular | |
Ranjita et al. | In-vitro release of paracetamol from suppocire suppositories: role of additives | |
WO2014076203A1 (fr) | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate | |
WO2007099559A2 (en) | Method of preparation for novel composition of 2-{(2,6 dichlorophenyl) amino] benzeneacetic acid carboxymethyl ester or 2-[2-[2-(2,6-dichlorophenyl) amino] phenylacetoxyacetic acid and method of its use | |
CN112439066A (zh) | 包含化学消融剂和pH调节剂的药物组合物及其应用 | |
CN110709105A (zh) | 载有药物的非水系组合物及其制备方法 | |
CN113262302B (zh) | 可注射长效半固体凝胶制剂 | |
WO2022143631A1 (zh) | 经口腔黏膜递送的丁苯酞组合物及其用途 | |
JP4672302B2 (ja) | 安定な局所麻酔組成物 | |
WO2024080884A1 (en) | Pharmaceutical compositions of tretinoin and methods of producing such compositions | |
BE829197A (fr) | Compositions anti-inflammatoires, leur preparation et leur utilisation | |
TW201028177A (en) | Hydrogel composition for the treatment of dermatological disorders | |
WO2010137696A1 (ja) | 口腔用薬剤組成物およびそれを封入した口腔用薬剤カプセル | |
UA75094C2 (uk) | Фармацевтична композиція, що містить сполуку модафінілу, та спосіб лікування |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180109 |
|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200806 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210208 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210218 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210316 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210322 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6857644 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |